TABLE 2. Chiapas facility-level data: status quo treatment schemes, 2020.
|
Chiapas | ||||
|---|---|---|---|---|
|
Risk factor category |
Medicines |
Dose per day |
% of people with the risk factor who are administered the treatment regimen |
Annual medication cost (USD) per patient |
|
Hypertension |
Telmisartan, amlodipine |
40 mg / 10 mg |
29.0% |
$18.0 |
|
Telmisartan, amlodipine |
40 mg / 5 mg |
19.0% |
$15.8 |
|
|
Telmisartan |
40 mg |
12.0% |
$13.6 |
|
|
Telmisartan, amlodipine, chlorthalidone |
40 mg / 5 mg / 50 mg |
11.0% |
$27.9 |
|
|
Captopril, hydrochlorothiazide |
25 mg / 25 mg |
9.0% |
$25.6 |
|
|
Enalapril, hydrochlorothiazide |
10 mg / 25 mg |
9.0% |
$14.3 |
|
|
Enalapril, hydrochlorothiazide, losartan |
10 mg / 25 mg / 50 mg |
6.0% |
$14.0 |
|
|
Losartan |
50 mg |
6.0% |
$6.8 |
|
|
Average annual per patient medication costs, hypertension → |
$17.59 |
|||
|
Diabetes |
Metformin, glibenclamide |
500 mg / 5 mg |
39.0% |
$11.21 |
|
Metformin, glibenclamide |
850 mg / 5 mg |
21.0% |
$12.29 |
|
|
Metformin, glibenclamide |
850 mg / 10 mg |
9.0% |
$5.47 |
|
|
Metformin, glibenclamide |
850 mg / 15 mg |
8.0% |
$10.19 |
|
|
Metformin, glibenclamide |
850 mg / 10 mg |
7.0% |
$8.88 |
|
|
Metformin |
500 mg |
7.0% |
$10.23 |
|
|
Metformin |
850 mg |
6.0% |
$10.23 |
|
|
Metformin |
850 mg |
2.0% |
$3.41 |
|
|
Average annual per patient medication costs, diabetes → |
$10.38 |
|||
|
Hyperlipidemia |
Pravastatin, bezafibrate |
10 mg / 200 mg |
4.0% |
$13.83 |
|
Bezafibrate |
200 mg |
2.0% |
$5.09 |
|
|
Pravastatin |
10 mg |
16.0% |
$3.41 |
|
|
Prevastatin |
20 mg |
55.0% |
$6.82 |
|
|
Prevastatin |
40 mg |
24.0% |
$13.64 |
|
|
Average annual per patient medication costs, hyperlipidemia → |
$8.14 |
|||